SLC13A5 and epilepsy: Mechanistically, we show that 1) pharmacological inhibition or genetic knockdown of NMDA receptor signaling, and 2) treatment with zinc rescues the epileptic phenotypes, serving as the first empirical evidence for the ‘chelation hypothesis’ of SLC13A5 epilepsy.